Immunotherapy for osteosarcoma

Kenichiro Yahiro, Yoshihiro Matsumoto

Research output: Contribution to journalArticlepeer-review

Abstract

Osteosarcoma (OS) is the most common malignant bone tumor and often occurs in children. Chemotherapy with methotrexate, cisplatin, doxorubicin, and ifosfamide has greatly improved the prognosis of patients with OS, and most patients have been able to preserve their limbs. However, no progress has been made in the treatment for OS in the past few decades, and the prognosis of patients with metastasis and/or local recurrence remains poor. Therefore, studies aimed at developing new treatment methods for OS are urgently required. Here, we discuss the current status of immunotherapies for OS as well as the current limitations in the field. In recent years, immunotherapy has been shown to be effective for treating several cancers, and its indication is continually increasing. Immunotherapy is also expected to be widely used for treating OS, however, the efficacy of immunotherapy for OS has not been established.

Original languageEnglish
Pages (from-to)1294-1295
Number of pages2
JournalHuman Vaccines and Immunotherapeutics
Volume17
Issue number5
DOIs
Publication statusPublished - 2021

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Fingerprint

Dive into the research topics of 'Immunotherapy for osteosarcoma'. Together they form a unique fingerprint.

Cite this